|
|
|
|
|
Delaware
|
|
001-36483
|
|
47-1187261
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
6200 Lookout Rd.
Boulder, CO
|
|
80301
|
(Address of principal executive offices)
|
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
Executive Officer and Principal Position
|
|
Bonus Amount
|
|
|
William S. Marshall, Ph.D.
|
|
$
|
147,000
|
|
President and Chief Executive Officer
|
|
|
|
|
Jason A. Leverone
|
|
$
|
71,400
|
|
Chief Financial Officer, Secretary and Treasurer
|
|
|
|
|
Adam S. Levy
|
|
$
|
82,800
|
|
Chief Business Officer
|
|
|
|
|
Paul D. Rubin, M.D.
|
|
$
|
98,400
|
|
Executive Vice President, Research and Development
|
|
|
|
|
|
|
|
|
|
Executive Officer and Principal Position
|
|
No. of Shares
subject to
Option
|
|
|
William S. Marshall, Ph.D.
|
|
|
232,000
|
|
President and Chief Executive Officer
|
|
|
|
|
Jason A. Leverone
|
|
|
75,000
|
|
Chief Financial Officer, Secretary and Treasurer
|
|
|
|
|
Adam S. Levy
|
|
|
74,000
|
|
Chief Business Officer
|
|
|
|
|
Paul D. Rubin, M.D.
|
|
|
87,000
|
|
Executive Vice President, Research and Development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive Officer and Principal Position
|
|
2019 Base
Salary
|
|
|
Bonus
Target
(1)
|
|
||
William S. Marshall, Ph.D.
|
|
$
|
521,000
|
|
|
|
50
|
%
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
Jason A. Leverone
|
|
$
|
355,000
|
|
|
|
40
|
%
|
Chief Financial Officer, Secretary and Treasurer
|
|
|
|
|
|
|
|
|
Adam S. Levy
|
|
$
|
345,000
|
|
|
|
40
|
%
|
Chief Business Officer
|
|
|
|
|
|
|
|
|
Paul D. Rubin, M.D.
|
|
$
|
426,000
|
|
|
|
40
|
%
|
Executive Vice President, Research and Development
|
|
|
|
|
|
|
|
|
|
|
|
||||||
(1) Bonus Targets listed as percentage of 2019 Base Salary
|
|
|
|
|
|
|
|
|
•
|
goals related to executing and further defining our development plan for Cobomarsen, our clinical product candidate for the treatment of certain cancers;
|
•
|
goals related to executing our development plan for Remlarsen, our clinical product candidate for the treatment of fibrosis;
|
•
|
goals related to executing our development plan for MRG-110, our clinical product candidate for the treatment of heart failure and other ischemic disease;
|
•
|
goals related to the development of our pre-clinical product candidate pipeline; and
|
•
|
finance and business development goals.
|
|
|
|
|
|
|
|
|
|
|
|
Miragen Therapeutics, Inc.
|
||
Date: February 8, 2019
|
|
|
|
|
||
|
|
|
|
|||
|
|
|
|
By:
|
|
/s/ Jason A. Leverone
|
|
|
|
|
|
|
Jason A. Leverone
|
|
|
|
|
|
|
Chief Financial Officer
|